{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:47:15Z","timestamp":1782532035790,"version":"3.54.5"},"reference-count":39,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.1248\/bpb.b26-00168","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:10:18Z","timestamp":1782166218000},"page":"989-995","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing the Norepinephrine Transporter Expression and [&lt;sup&gt;211&lt;\/sup&gt;At]MABG Uptake with Vorinostat Preloading in the Pheochromocytoma Model"],"prefix":"10.1248","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-3779","authenticated-orcid":false,"given":"Yasuhiro","family":"Ohshima","sequence":"first","affiliation":[{"name":"Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Takasaki, Gunma 370\u20131292, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Takasaki, Gunma 370\u20131292, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Takasaki, Gunma 370\u20131292, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata, Osaka 573\u20131010, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Ukon","sequence":"additional","affiliation":[{"name":"Advanced Clinical Research Center, Fukushima Medical University, Fukushima 960\u20131295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sakashita","sequence":"additional","affiliation":[{"name":"Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Takasaki, Gunma 370\u20131292, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko S.","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Takasaki, Gunma 370\u20131292, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. <i>Nat. Rev. Drug Discov.<\/i>, <b>19<\/b>, 589\u2013608 (2020).","DOI":"10.1038\/s41573-020-0073-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. <i>J. Nucl. Med.<\/i>, <b>57<\/b>, 1941\u20131944 (2016).","DOI":"10.2967\/jnumed.116.178673"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy <i>versus<\/i> HER2\/neu expression. <i>Clin. Cancer Res.<\/i>, <b>10<\/b>, 4489\u20134497 (2004).","DOI":"10.1158\/1078-0432.CCR-03-0800"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lind\u00e9n O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. <sup>227<\/sup>Th-labeled anti-CD22 antibody (BAY 1862864) in relapsed\/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, phase I study. <i>Cancer Biother. Radiopharm.<\/i>, <b>36<\/b>, 672\u2013681 (2021).","DOI":"10.1089\/cbr.2020.4653"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Demirci E, Alan Sel\u00e7uk N, Beyda\u011f\u0131 G, Ocak M, Toklu T, Ak\u00e7ay K, Kabasakal L. Initial findings on the use of [<sup>225<\/sup>Ac]Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors. <i>Mol. Imaging Radionucl. Ther.<\/i>, <b>32<\/b>, 226\u2013232 (2023).","DOI":"10.4274\/mirt.galenos.2023.38258"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with <sup>225<\/sup>Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. <i>J. Nucl. Med.<\/i>, <b>59<\/b>, 795\u2013802 (2018).","DOI":"10.2967\/jnumed.117.203539"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) McAbee JH, Degorre-Kerbaul C, Valdez K, Wendler A, Shankavaram UT, Watts C, Camphausen K, Tofilon PJ. Detection of glioblastoma intratumor heterogeneity in radiosensitivity using patient-derived neurosphere cultures. <i>J. Neurooncol.<\/i>, <b>149<\/b>, 383\u2013390 (2020).","DOI":"10.1007\/s11060-020-03643-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Puranik AD, Dromain C, Fleshner N, Sathekge M, Pavel M, Eberhardt N, Zengerling F, Marienfeld R, Grunert M, Prasad V. Target heterogeneity in oncology: the best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer. <i>Cancers<\/i>, <b>13<\/b>, 3607 (2021).","DOI":"10.3390\/cancers13143607"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dom\u00ednguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. <i>N. Engl. J. Med.<\/i>, <b>368<\/b>, 623\u2013632 (2013).","DOI":"10.1056\/NEJMoa1209288"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. <i>Clin. Cancer Res.<\/i>, <b>21<\/b>, 1028\u20131035 (2015).","DOI":"10.1158\/1078-0432.CCR-14-2915"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Pugliese M, Fortunati N, Germano A, Asioli S, Marano F, Palestini N, Frairia R, Boccuzzi G, Catalano MG. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. <i>Thyroid<\/i>, <b>23<\/b>, 838\u2013846 (2013).","DOI":"10.1089\/thy.2012.0359"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, Dubois SG, Matthay KK, Giacomini KM. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma <i>in vitro<\/i> and <i>in vivo<\/i> model systems. <i>Clin. Cancer Res.<\/i>, <b>17<\/b>, 2339\u20132349 (2011).","DOI":"10.1158\/1078-0432.CCR-10-2949"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, Kiesewetter DO, Thomasson D, Morris JC, Kvetnansky R, Tischler AS, Reynolds JC, Fojo AT, Pacak K. Increased uptake of [<sup>123<\/sup>I]meta-iodobenzylguanidine, [<sup>18<\/sup>F]fluorodopamine, and [<sup>3<\/sup>H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. <i>Endocr. Relat. Cancer<\/i>, <b>18<\/b>, 143\u2013157 (2011).","DOI":"10.1677\/ERC-10-0090"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) DuBois SG, Groshen S, Park JR, <i>et al<\/i>. Phase I Study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. <i>Clin. Cancer Res.<\/i>, <b>21<\/b>, 2715\u20132721 (2015).","DOI":"10.1158\/1078-0432.CCR-14-3240"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pollard JH, Menda Y, Zamba KD, Madsen M, O\u2019Dorisio MS, O\u2019Dorisio T, Bushnell D. Potential for increasing uptake of radiolabeled <sup>68<\/sup>Ga-DOTATOC and <sup>123<\/sup>I-MIBG in patients with midgut neuroendocrine tumors using a histone deacetylase inhibitor vorinostat. <i>Cancer Biother. Radiopharm.<\/i>, <b>36<\/b>, 632\u2013641 (2021).","DOI":"10.1089\/cbr.2020.4633"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, Sakashita T, Ito YM, Yoshinaga K, Higashi T, Ishioka NS. Antitumor effects of radionuclide treatment using \u03b1-emitting meta-<sup>211<\/sup>At-astato-benzylguanidine in a PC12 pheochromocytoma model. <i>Eur. J. Nucl. Med. Mol. Imaging<\/i>, <b>45<\/b>, 999\u20131010 (2018).","DOI":"10.1007\/s00259-017-3919-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bliss CI. The toxicity of poisons applied jointly. <i>Ann. Appl. Biol.<\/i>, <b>26<\/b>, 585\u2013615 (1939).","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ohshima Y, Sasaki I, Watanabe S, Sakashita T, Higashi T, Ishioka NS. Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[<sup>211<\/sup>At]astato-benzylguanidine. <i>Nucl. Med. Biol.<\/i>, <b>112-113<\/b>, 44\u201351 (2022).","DOI":"10.1016\/j.nucmedbio.2022.06.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Munekane M, Echigo H, Fuchigami T, Ogawa K. Probes with tailored pharmacokinetics for radiotheranostics. <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 1295\u20131318 (2025).","DOI":"10.1248\/bpb.b25-00195"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic performance of <sup>68<\/sup>Ga-DOTATATE PET\/CT, <sup>18<\/sup>F-FDG PET\/CT and <sup>131<\/sup>I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. <i>Nucl. Med. Mol. Imaging<\/i>, <b>49<\/b>, 143\u2013151 (2015).","DOI":"10.1007\/s13139-015-0331-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (<sup>131<\/sup>I-MIBG): a comprehensive review of 116 reported patients. <i>J. Endocrinol. Invest.<\/i>, <b>20<\/b>, 648\u2013658 (1997).","DOI":"10.1007\/BF03348026"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Daniel KB, Sullivan ED, Chen Y, Chan JC, Jennings PA, Fierke CA, Cohen SM. Dual-mode HDAC prodrug for covalent modification and subsequent inhibitor release. <i>J. Med. Chem.<\/i>, <b>58<\/b>, 4812\u20134821 (2015).","DOI":"10.1021\/acs.jmedchem.5b00539"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P, Beck-Popovic M, Grouzmann E, Abid K. CUDC-907, a dual PI3K\/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (<sup>123\/131<\/sup>I-mIBG) <i>in vitro<\/i> and <i>in vivo<\/i>: a promising candidate for advancing theranostics in neuroendocrine tumors. <i>J. Transl. Med.<\/i>, <b>21<\/b>, 604 (2023).","DOI":"10.1186\/s12967-023-04466-z"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. <i>Nat. Rev. Drug Discov.<\/i>, <b>5<\/b>, 769\u2013784 (2006).","DOI":"10.1038\/nrd2133"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Chueh AC, Tse JW, T\u00f6gel L, Mariadason JM. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. <i>Antioxid. Redox Signal.<\/i>, <b>23<\/b>, 66\u201384 (2015).","DOI":"10.1089\/ars.2014.5863"},{"key":"26","unstructured":"26) Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. <i>Mol. Cancer Ther.<\/i>, <b>2<\/b>, 151\u2013163 (2003). &lt;https:\/\/pubmed.ncbi.nlm.nih.gov\/12589032\/&gt;."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Harikrishnan KN, Bayles R, Ciccotosto GD, Maxwell S, Cappai R, Pelka GJ, Tam PP, Christodoulou J, El-Osta A. Alleviating transcriptional inhibition of the norepinephrine slc6a2 transporter gene in depolarized neurons. <i>J. Neurosci.<\/i>, <b>30<\/b>, 1494\u20131501 (2010).","DOI":"10.1523\/JNEUROSCI.4675-09.2010"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>101<\/b>, 1241\u20131246 (2004).","DOI":"10.1073\/pnas.0307708100"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. <i>Oncogene<\/i>, <b>23<\/b>, 5340\u20135349 (2004).","DOI":"10.1038\/sj.onc.1207689"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. <i>J. Biol. Chem.<\/i>, <b>280<\/b>, 38879\u201338887 (2005).","DOI":"10.1074\/jbc.M505733200"},{"key":"31","unstructured":"31) Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. <i>J. Nucl. Med.<\/i>, <b>34<\/b>, 1140\u20131146 (1993). &lt;https:\/\/pubmed.ncbi.nlm.nih.gov\/8315492\/&gt;."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Blom T, Meinsma R, Rutgers M, Buitenhuis C, Dekken-Van den Burg M, van Kuilenburg ABP, Tytgat GAM. Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake. <i>EJNMMI Res.<\/i>, <b>10<\/b>, 78 (2020).","DOI":"10.1186\/s13550-020-00662-w"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, Burnazi E, Finn RD, Doubrovin M, Blasberg RG. Imaging hNET reporter gene expression with 124I-MIBG. <i>J. Nucl. Med.<\/i>, <b>48<\/b>, 827\u2013836 (2007).","DOI":"10.2967\/jnumed.106.037812"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Zhou J. Norepinephrine transporter inhibitors and their therapeutic potential. <i>Drugs Future<\/i>, <b>29<\/b>, 1235\u20131244 (2004).","DOI":"10.1358\/dof.2004.029.12.855246"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ohshima Y, Kono N, Yokota Y, Watanabe S, Sasaki I, Ishioka NS, Sakashita T, Arakawa K. Anti-tumor effects and potential therapeutic response biomarkers in \u03b1-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing. <i>Theranostics<\/i>, <b>9<\/b>, 1538\u20131549 (2019).","DOI":"10.7150\/thno.30353"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. <i>Int. J. Radiat. Oncol. Biol. Phys.<\/i>, <b>62<\/b>, 223\u2013229 (2005).","DOI":"10.1016\/j.ijrobp.2004.12.088"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown <i>in vitro<\/i> and as intracranial xenografts. <i>Mol. Cancer Ther.<\/i>, <b>8<\/b>, 1589\u20131595 (2009).","DOI":"10.1158\/1535-7163.MCT-09-0038"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Fujiwara Y, Yamamoto N, Yamada Y, Yamada K, Otsuki T, Kanazu S, Iwasa T, Hardwick JS, Tamura T. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. <i>Cancer Sci.<\/i>, <b>100<\/b>, 1728\u20131734 (2009).","DOI":"10.1111\/j.1349-7006.2009.01237.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>94<\/b>, 4757\u20134767 (2009).","DOI":"10.1210\/jc.2009-1248"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b26-00168\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:24:47Z","timestamp":1782530687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b26-00168\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00168","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"b26-00168"}}